Anito-cel Yields Durable Responses in Multiple Myeloma

Managing heavily pretreated relapsed or refractory multiple myeloma presents significant clinical challenges. Recent phase 1 clinical trial results highlight the promise of anito-cel in multiple myeloma. This autologous chimeric antigen receptor (CAR) T-cell therapy incorporates a novel synthetic d-domain binder directed against B-cell maturation antigen. Consequently, the unique construct provides distinct pharmacological advantages over traditional CAR T cells. Clinicians now have encouraging evidence regarding its therapeutic value.

Clinical Efficacy of Anito-cel in Multiple Myeloma

The phase 1 trial enrolled 40 patients with advanced relapsed or refractory disease. Overall, 38 patients received the study infusion after lymphodepletion. At a median follow-up of 38.1 months, all 38 patients achieved an objective clinical response. Furthermore, 79% of these individuals reached a complete response. The therapy demonstrated remarkable durability in this difficult population. Specifically, the median progression-free survival reached 30.2 months. The 24-month progression-free survival rate stood at 57%. In addition, the 36-month overall survival rate reached 65%.

Favorable Safety Profile and Reduced Neurotoxicity

Safety outcomes in this trial proved notably distinct from existing BCMA-directed CAR T products. Although 97% of patients developed grade 3 or higher adverse events, severe systemic complications remained infrequent. For example, 94% of patients receiving the recommended phase 2 dose developed cytokine release syndrome. However, all cases were mild or moderate, with zero grade 3 or higher events. Similarly, only 16% of patients developed low-grade immune effector cell-associated neurotoxicity syndrome. Only one patient experienced grade 3 neurotoxicity. Importantly, investigators reported no delayed neurotoxicity or movement disorders.

Distinct d-Domain Mechanism

The novel synthetic d-domain binder contributes directly to this balanced therapeutic profile. Laboratory studies compared the ddBCMA binder to standard dual heavy-chain antibody binders. Notably, the ddBCMA construct demonstrated a much faster off-rate. Consequently, the engineered T cells sustained robust cytotoxicity while releasing fewer systemic inflammatory cytokines. The cells also avoided ligand-independent tonic signaling and off-target killing. Therefore, this targeted design may offer oncologists looking to advance their expertise through a certification course in hematology a safer cellular therapy alternative.

Frequently Asked Questions

Q1: What is anito-cel and how does it target multiple myeloma?

Anito-cel is an autologous BCMA-directed CAR T-cell therapy. Furthermore, it utilizes a compact synthetic d-domain binder to clear malignant plasma cells efficiently.

Q2: What response rates did anito-cel show in the phase 1 trial?

In this trial, 100% of treated patients achieved an objective response. In addition, 79% achieved a complete response, with a median progression-free survival of 30.2 months.

Q3: Did patients experience severe delayed neurotoxicity with anito-cel?

No, investigators observed zero delayed neurotoxic events or movement disorders. Therefore, anito-cel demonstrated an encouraging safety profile compared with older BCMA therapies. Practitioners seeking comprehensive education can explore various hematology speciality courses for deeper insights into modern cancer care.

References

1. Frigault MJ et al. Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma. N Engl J Med. 2026 Sep 24. doi: 10.1056/NEJMoa2603527. PMID: 42777241.
2. Kumar SK et al. Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv. 2023;7(7):1224-1233.
3. Bishop MR et al. Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up. Blood. 2024;144(Suppl 1):1018.